Nabriva Therapeutics PLC (NBRVF)

[John-Knee]

Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
2020-11-02 04:02:21 PM ET (GlobeNewswire)
   
   
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results after the close of the U.S. financial markets on Thursday, November 5, 2020. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 for international participants, with Conference ID #5564729. A live webcast of the conference call can be accessed through the "Investors" tab on the Nabriva Therapeutics website at www.nabriva.com. A replay will be available on this website shortly after conclusion of the event for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin), the first pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing Contepo(TM) (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. For more information, please visit https://www.nabriva.com.